| Psoriasis vulgaris

Enstilar vs Stelara

Side-by-side clinical, coverage, and cost comparison for psoriasis vulgaris.

Deep comparison between: Enstilar vs Stelara with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsStelara has a higher rate of injection site reactions vs Enstilar based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Stelara but not Enstilar, including UnitedHealthcare

Category

Enstilar

Stelara

At A Glance

RouteTopical

FrequencyOnce daily

ClassVitamin D3 analog + corticosteroid

RouteSC injection

FrequencyEvery 8-12 weeks

ClassIL-12/23 antagonist

Indications

Psoriasis vulgaris

Psoriasis vulgaris
Arthritis, Psoriatic
Crohn Disease
Ulcerative Colitis

Dosing

Psoriasis vulgaris Apply to affected areas once daily for up to 4 weeks; maximum dose not to exceed 60 g every 4 days; rub in gently; do not use with occlusive dressings, on the face, groin, or axillae, or if skin atrophy is present at the treatment site.

Psoriasis vulgaris Adults <=100 kg: 45 mg SC at weeks 0 and 4, then every 12 weeks; adults >100 kg: 90 mg SC at weeks 0 and 4, then every 12 weeks; pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for 60-100 kg, 90 mg for >100 kg) SC at weeks 0 and 4, then every 12 weeks.

Arthritis, Psoriatic Adults: 45 mg SC at weeks 0 and 4, then every 12 weeks (90 mg for >100 kg with co-existent moderate-to-severe plaque psoriasis); pediatric patients >=6 years: weight-based dosing (0.75 mg/kg for <60 kg, 45 mg for >=60 kg, 90 mg for >100 kg with co-existent plaque psoriasis) SC at weeks 0 and 4, then every 12 weeks.

Crohn Disease, Ulcerative Colitis Adults: single IV induction dose (260 mg for <=55 kg, 390 mg for >55-85 kg, 520 mg for >85 kg), followed by 90 mg SC at week 8, then every 8 weeks.

Contraindications

—

Clinically significant hypersensitivity to ustekinumab or any excipient of STELARA

Drug Interactions

841View drug interactions

969View drug interactions

Adverse Reactions

Postmarketing Application site burning, atrophy, striae, telangiectasia, dryness, perioral dermatitis, secondary infection, miliaria, cataracts, glaucoma, increased intraocular pressure.

Most common (>=1%) Nasopharyngitis, upper respiratory tract infection, headache, fatigue, back pain, dizziness, pharyngolaryngeal pain, pruritus, injection site erythema, myalgia, depression

Serious Infections, malignancies, serious hypersensitivity reactions, posterior reversible encephalopathy syndrome (PRES), noninfectious pneumonia

Postmarketing Hypersensitivity reactions (anaphylaxis, angioedema, dyspnea, rash, urticaria), lower respiratory tract infection, PRES, interstitial pneumonia, eosinophilic pneumonia, cryptogenic organizing pneumonia, pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis

Pharmacology

Enstilar Foam combines calcipotriene hydrate, a synthetic vitamin D3 analog, and betamethasone dipropionate, a synthetic corticosteroid; exact mechanisms of action in the treatment of plaque psoriasis are unknown.

Ustekinumab is a human IgG1k monoclonal antibody that binds the p40 protein subunit shared by IL-12 and IL-23, blocking their interaction with the IL-12Rb1 receptor chain and thereby suppressing downstream inflammatory signaling involved in natural killer cell activation and CD4+ T-cell differentiation and activation.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Enstilar